Average Co-Inventor Count = 3.39
ph-index = 13
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Nestec S.a. (30 from 2,370 patents)
2. Sony Corporation (10 from 58,114 patents)
3. Sony Group Corporation (10 from 3,158 patents)
4. Biora Therapeutics, Inc. (10 from 17 patents)
5. Progenity, Inc. (8 from 19 patents)
6. SociÉtÉ Des Produits NestlÉ S.a. (7 from 181 patents)
7. Prometheus Laboratories Inc. (6 from 20 patents)
8. Sony Corporation of America (3 from 184 patents)
9. Pierian Holdings, Inc. (3 from 3 patents)
10. Prometheus Biosciences, Inc. (2 from 14 patents)
11. Enumera Molecular, Inc. (2 from 4 patents)
12. Other (1 from 831,952 patents)
13. Katholieke Universiteit Leuven (1 from 340 patents)
14. Monogram Biosciences, Inc. (1 from 52 patents)
15. Prometheus Biosiences, Inc. (1 from 1 patent)
93 patents:
1. 12391833 - Polymeric dyes with linker groups comprising deoxyribose
2. 12319817 - Polymeric tandem dyes with linker groups
3. 12275851 - Polymeric tandem dyes with linker groups
4. 12270812 - Ultra bright dimeric or polymeric dyes with spacing linker groups
5. 12227565 - Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
6. 12171764 - Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
7. 12150775 - Treatment of a disease of the gastrointestinal tract with an immunosuppressant
8. 12145956 - Programmable polymeric drugs
9. 12098161 - Programmable polymeric drugs
10. 12089916 - Gastrointestinal tract detection methods, devices and systems
11. 12006438 - Polymeric dyes with linker groups comprising deoxyribose
12. 11981820 - Ultra bright dimeric or polymeric dyes
13. 11959129 - Methods, systems, and compositions for counting nucleic acid molecules
14. 11874280 - Use of divalent metals for enhancement of fluorescent signals
15. 11857669 - Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices